EMA Authorised: Jinarc (tolvaptan) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

Authorised status for Jinarc (tolvaptan) for polycystic kidney disease due to autosomal dominant inheritance, implemented by Otsuka Pharmaceutical Netherlands B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JINARC (tolvaptan)

Snippet

Status: Authorised. Therapeutic area: Polycystic Kidney, Autosomal Dominant. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 18/08/2026